Biotechnology Regulation · us
From Manufacturing to Release: FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
Whether a batch of a therapy delivers its expected biological activity depends on how materials, manufacturing processes, and testing work together to ensure quality. FDA has updated guidance used for 15 years, extending its quality management perspective across the entire product lifecycle while retaining flexibility based on the stage of development.
For patients receiving cell or gene therapies, every batch delivered to the bedside must have the biological activity needed to perform its intended function. Establishing that assurance involves the entire manufacturing chain, from starting materials to the finished product. On November 2, the U.S. Food and Drug Administration (FDA) issued final potency assurance guidance that brings process design, material controls, and testing into a shared framework, replacing its 2011 potency testing guidance.
Here, “potency” refers to a product’s specific ability to achieve its intended therapeutic effect. It is an important part of quality assessment and cannot be directly equated with the clinical benefit patients actually receive. The new guidance recommends that manufacturers use scientific evidence and risk assessment to combine process design, process controls, material controls, in-process testing, and lot release potency assays to reduce the risk of insufficient or inconsistent product activity.
This approach moves the starting point for quality assurance further upstream. FDA’s priorities include variability in starting materials, testing during manufacturing, and laboratory testing to confirm that a product’s biological activity aligns with its intended function. The document also addresses considerations for therapies with short shelf lives, those that use viral vectors, and those manufactured for individual patients, reflecting the reality that different products cannot readily share a single testing approach.
Expectations also become more extensive as development progresses. From early investigational new drug applications (INDs) through biologics license applications (BLAs) and ongoing postmarketing confirmation, developers need to progressively build their understanding of the product and its manufacturing process. For licensed products, potency testing should generally take place after all manufacturing steps that could affect potency have been completed; alternative approaches must provide an equal or greater level of potency assurance. FDA also encourages developers to seek regulatory feedback early on their strategies and assay methods.
A November 3 Federal Register notice confirmed that the document finalizes the draft issued on December 28, 2023, and applies to cell and gene therapy biological products regulated under Section 351 of the Public Health Service Act. Compared with the draft, the final guidance adds details on integration with existing quality systems, conducting risk assessments, and pathways for communicating with regulators, along with more practical examples.
A summary by AABB, a professional organization for blood and biotherapies, notes that the final guidance retains the draft’s framework while placing greater emphasis on flexibility appropriate to the stage of development, and that potency assurance can be incorporated into companies’ existing quality systems. AABB also notes that FDA narrowed the relevant clinical hold language to focus on situations in which inadequate potency assurance exposes participants to an unreasonable and significant risk, or an IND lacks necessary potency information.
The guidance itself is not legally binding, and companies may use other approaches that comply with applicable regulations. It offers direction for establishing evidence of quality; it neither demonstrates the efficacy of any therapy nor provides a universal potency threshold for all products. For development teams, the next task is to translate these principles into quality strategies that reflect their products’ functions and can be continually evaluated as manufacturing processes and stages of development evolve.